cell therapy clinical trial intelligence

Phase I Study to Evaluate the Safety and Efficacy of NK Cell Therapy in Acute Myeloid Leukemia (AML).

Phase I Study to Evaluate the Safety and Efficacy of NK Cell Therapy in Acute Myeloid Leukemia (AML). is a PHASE1 clinical asset sponsored by Institute of Hematology & Blood Diseases Hospital, China in AML, Adult, Minimal Residual Disease. SEO and diligence focus: CD33/CLL1 dual CAR-NK cell, Cyclophosphamid, Fludarabine, Cytarabine, CD33 CAR-NK cell, super NK cell, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: cell therapy

Safety, Tolerability and Efficacy of Enhanced IL-13Rα2 Targeted Chimeric Antigen Receptor T Cell Immunotherapy Against Recurrent/Refractory Grade 4 Glioma

Safety, Tolerability and Efficacy of Enhanced IL-13Rα2 Targeted Chimeric Antigen Receptor T Cell Immunotherapy Against Recurrent/Refractory Grade 4 Glioma is a PHASE1 clinical asset sponsored by Yang Zhang in Glioma. SEO and diligence focus: IL13Rα2 CAR-T, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: cell therapy

Open-label, Phase I, Multi-center Study to Determine in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients the Recommended Dose of CYAD-02 After a Non-myeloablative Preconditioning Chemotherapy Followed by a Potential Consolidation Cycle

Open-label, Phase I, Multi-center Study to Determine in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients the Recommended Dose of CYAD-02 After a Non-myeloablative Preconditioning Chemotherapy Followed by a Potential Consolidation Cycle is a PHASE1 clinical asset sponsored by Celyad Oncology SA in Acute Myeloid Leukemia, Myelodysplastic Syndrome. SEO and diligence focus: CYAD-02, ENDOXAN, Fludara, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: cell therapy

A Phase I, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor Patients

A Phase I, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor Patients is a PHASE1 clinical asset sponsored by Beijing Boren Hospital in T Cell Lymphoma, T-cell Leukemia. SEO and diligence focus: Efficacy of LCAR-T2C CAR-T cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: cell therapy

Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma

Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma is a PHASE1 clinical asset sponsored by Zhejiang University in Advanced Hepatocellular Carcinoma. SEO and diligence focus: anti-GPC3 CAR-T, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: cell therapy

A Long-term Follow-up Study of Patients Who Received VOR33

A Long-term Follow-up Study of Patients Who Received VOR33 is a registry-stage clinical asset sponsored by Vor Biopharma in Leukemia, Myeloid, Acute. SEO and diligence focus: VOR33, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: cell therapy

Clinical Trial for the Safety and Efficacy of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma

Clinical Trial for the Safety and Efficacy of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma is a PHASE2 clinical asset sponsored by Zhejiang University in Multiple Myeloma, New Diagnosis Tumor. SEO and diligence focus: BCMA CAR-T cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: cell therapy

A Phase Ⅰb Study Evaluating Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor T-cell (C-CAR011) Treatment in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

A Phase Ⅰb Study Evaluating Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor T-cell (C-CAR011) Treatment in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma is a PHASE1 clinical asset sponsored by Peking Union Medical College Hospital in B-cell Non-Hodgkin Lymphoma. SEO and diligence focus: CD19-directed CAR-T cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: cell therapy

Brain Function and Psychological Assessment in Patients With Autoimmune Hemolytic Anemia Undergoing Cell Therapy

Brain Function and Psychological Assessment in Patients With Autoimmune Hemolytic Anemia Undergoing Cell Therapy is a registry-stage clinical asset sponsored by Institute of Hematology & Blood Diseases Hospital, China in CAR T-cell Therapy, Autoimmune Hemolytic Anemia, Brain Function, Psychological Well-Being. SEO and diligence focus: Brain function and psychological assessment, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: cell therapy

Phase Ib Clinical Study of BCMA-Targeted Chimeric Antigen Receptor T-Cell Injection (CART-BCMA) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Phase Ib Clinical Study of BCMA-Targeted Chimeric Antigen Receptor T-Cell Injection (CART-BCMA) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma is a EARLY_PHASE1 clinical asset sponsored by Chulalongkorn University in Relapsed/Refractory Multiple Myeloma (MM). SEO and diligence focus: Chimeric Antigen Receptor T Cells (CAR-T), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: cell therapy

An Exploratory Clinical Study of the Safety and Efficacy of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas

An Exploratory Clinical Study of the Safety and Efficacy of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas is a PHASE1 clinical asset sponsored by Affiliated Hospital of Nantong University in Relapsed/Refractory B-cell Lymphoma. SEO and diligence focus: RN1701 injection, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: cell therapy

A Single Center, Open-Label, Phase I Study to Evaluate the Safety, Tolerance, and Efficacy of Allogeneic LB-DTK-COV19 Cells in Severe Coronavirus Disease 2019 Patients

A Single Center, Open-Label, Phase I Study to Evaluate the Safety, Tolerance, and Efficacy of Allogeneic LB-DTK-COV19 Cells in Severe Coronavirus Disease 2019 Patients is a PHASE1 clinical asset sponsored by LucasBio in COVID-19, COVID-19 (SARS-CoV-2 Infection). SEO and diligence focus: LB-DTK-COV19, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: cell therapy

Safety and Efficiency of BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT: a Prospective, Single-arm, Single-center, Phase II Study.

Safety and Efficiency of BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT: a Prospective, Single-arm, Single-center, Phase II Study. is a PHASE2 clinical asset sponsored by Institute of Hematology & Blood Diseases Hospital, China in Multiple Myeloma. SEO and diligence focus: anti-BCMA CAR-T, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: cell therapy

Efficacy and Safety of Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma：a Single-center, Open-label, Pragmatic Clinical Trial

Efficacy and Safety of Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma：a Single-center, Open-label, Pragmatic Clinical Trial is a PHASE3 clinical asset sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology in Diffuse Large B Cell Lymphoma, Burkitt Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma. SEO and diligence focus: BTK inhibitor+ Fludarabine-based chemotherapy + CAR-T-CD19 Cells, Fludarabine-based chemotherapy + CAR-T-CD19 Cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: cell therapy

A Phase 1/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of IMPT-514 in Participants With Active, Refractory Lupus Nephritis and Systemic Lupus Erythematosus

A Phase 1/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of IMPT-514 in Participants With Active, Refractory Lupus Nephritis and Systemic Lupus Erythematosus is a PHASE1 clinical asset sponsored by Lyell Immunopharma, Inc. in Systemic Lupus Erythematosus, Lupus Nephritis. SEO and diligence focus: IMPT-514, IMPT-514, IMPT-514, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: cell therapy

A Multi-Center Study of Multiple CAR T Cell Therapy for CD7-positive Hematological Malignancies

A Multi-Center Study of Multiple CAR T Cell Therapy for CD7-positive Hematological Malignancies is a PHASE1 clinical asset sponsored by Shenzhen Geno-Immune Medical Institute in T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia, NK Cell Lymphoma. SEO and diligence focus: CD7-specific CAR gene-engineered T cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: cell therapy

Study of CAR-T Cells Targeting BCMA for Previously CAR-T Treated Refractory/Relapsed Multiple Myeloma

Study of CAR-T Cells Targeting BCMA for Previously CAR-T Treated Refractory/Relapsed Multiple Myeloma is a PHASE1 clinical asset sponsored by Second Affiliated Hospital of Xi'an Jiaotong University in Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma Progression. SEO and diligence focus: CAR-T Re-treatment, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: cell therapy

Multicenter, Single-Arm Exploratory Phase I Clinical Study on the Safety and Efficacy of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Participants With Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma

Multicenter, Single-Arm Exploratory Phase I Clinical Study on the Safety and Efficacy of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Participants With Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma is a PHASE1 clinical asset sponsored by Institute of Hematology & Blood Diseases Hospital, China in DLBCL, CLL, FL, MCL, WM, MZL. SEO and diligence focus: BAFF-R CAR-T, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: cell therapy

Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity Following CAR-T Infusion on an Outpatient Basis

The trial aimed to evaluate the feasibility of telemedicine in monitoring patients undergoing CAR-T therapy for relapsed or refractory large B-cell lymphoma. Given the increasing adoption of telehealth solutions, especially post-COVID-19, this approach could enhance patient management and reduce healthcare costs. However, the trial was withdrawn, indicating potential challenges in execution or strategic alignment. The market for CAR-T therapies is expanding, with significant competition from established players and emerging biotech firms. Companies should consider the implications of telemedicine integration in their CAR-T programs to improve patient outcomes and operational efficiencies.

Matched by modality_normalized: cell therapy

A Phase 1b, Open-label, Multi-cohort Study of AZD0120, an Autologous CD19/BCMA Targeting Chimeric Antigen Receptor T-cell, in Adults With Autoimmune Diseases

AstraZeneca's AZD0120 is positioned in the emerging CAR T-cell therapy market, targeting autoimmune diseases such as systemic sclerosis, idiopathic inflammatory myopathies, and difficult-to-treat rheumatoid arthritis. The dual targeting mechanism may provide a competitive edge over existing therapies, particularly in indications with high unmet needs. The trial's multi-cohort design allows for the exploration of efficacy across different autoimmune conditions, potentially expanding the market reach. Given the increasing prevalence of autoimmune diseases and the limitations of current treatments, successful outcomes could lead to significant commercial opportunities. However, the presence of established competitors in the CAR T-cell space necessitates careful monitoring of trial results and market dynamics.

Matched by modality_normalized: cell therapy

Sequential Infusion of CD19 and BCMA Chimeric Antigen Receptor T Cells to Improve Alloimmune-mediated Platelet Transfusion Refractoriness in Patients With Acute Leukemia in Complete Remission

This clinical trial, sponsored by The First Affiliated Hospital of Soochow University, aims to address alloimmune-mediated platelet transfusion refractoriness (PTR) in patients with acute leukemia in complete remission. The market for therapies targeting PTR is significant, given the high incidence of this condition in acute leukemia patients, particularly during the myelosuppression period post-chemotherapy. Current management strategies have proven largely unsatisfactory, creating an opportunity for innovative therapies like CAR-T cell treatments. The involvement of multiple collaborating hospitals and a biotech company indicates a robust support network, which may enhance the trial's credibility and potential for commercialization. If successful, this therapy could capture a niche market within hematology, particularly among patients who are refractory to existing treatments.

Matched by modality_normalized: cell therapy

A Single-arm, Open-label Clinical Study Evaluating the Efficacy and Safety of U01 (ssCART-19) in Patients With Relapsed or Refractory B-cell Lymphoma.

U01 (ssCART-19) is positioned to address a significant unmet need in the treatment of relapsed or refractory B-cell lymphoma, a market characterized by high demand for innovative therapies. The asset is currently in Phase 1 clinical trials, with recruitment ongoing at Tongji Hospital in Shanghai, China. The competitive landscape includes established CAR-T therapies such as Kymriah and Yescarta, which have demonstrated efficacy but also present challenges related to safety and tolerability. The incorporation of an IL-6 silencing element may provide a differentiated safety profile, potentially enhancing market acceptance and adoption. Successful outcomes could lead to expedited pathways for regulatory approval, particularly in regions with high incidence rates of B-cell lymphoma.

Matched by modality_normalized: cell therapy

A Single-Center, Prospective Study Evaluating the Efficacy and Safety of CAR T-cell Therapy in Combination With Glofitamab in the Treatment of Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors

This clinical trial, sponsored by Ruijin Hospital, aims to evaluate the combined efficacy and safety of CAR T-cell therapy and Glofitamab in patients with relapsed/refractory large B-cell lymphoma exhibiting high-risk prognostic factors. The market for CAR T-cell therapies is expanding, particularly in hematologic malignancies, with increasing competition from other CAR T-cell products and bispecific antibodies. Successful outcomes could position this combination therapy as a viable treatment option, potentially capturing market share in a segment characterized by high unmet medical need. Diligence should focus on the competitive landscape, particularly the performance of existing therapies and ongoing trials targeting similar patient populations.

Matched by modality_normalized: cell therapy

An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies

OriV508, developed by Union Hospital and OriCell Therapeutics, targets relapsed/refractory hematological malignancies, specifically multiple myeloma and aggressive B-cell non-Hodgkin lymphoma. The market for CAR-T therapies is rapidly expanding, with significant competition from established players like Novartis and Gilead. Successful outcomes in this trial could position OriV508 as a viable treatment option, potentially capturing market share in a high-demand segment. The trial's single-arm design and focus on safety and preliminary efficacy will be critical for attracting investment and partnership opportunities, especially given the stringent eligibility criteria that may limit patient enrollment.

Matched by modality_normalized: cell therapy

Phase I/II Study to Evaluate Treatment of Relapsed or Refractory Leukemia and Lymphoma With Universal CRISPR-Cas9 Gene-Editing CAR-T Cells Targeting CD19 and CD20 or CD22

The study, sponsored by the Chinese PLA General Hospital, aims to evaluate the safety and feasibility of a novel allogenic gene-edited CAR-T cell therapy targeting CD19 and CD20 or CD22 in patients with relapsed or refractory B-cell malignancies. The dual specificity approach addresses the challenge of CD19 loss in tumor cells, potentially expanding the therapeutic window for CAR-T therapies in this patient population. Given the increasing prevalence of hematological malignancies and the limitations of current CAR-T therapies, this asset may capture significant market interest, particularly in regions with high unmet medical needs. The competitive landscape includes established CAR-T therapies like Kymriah and Yescarta, but the dual-targeting mechanism may provide a differentiated offering. Diligence should focus on regulatory pathways, manufacturing scalability, and potential partnerships for commercialization.

Matched by modality_normalized: cell therapy

Phase I Study of CRISPR-Cas9 Mediated PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells With the Conditioning Regimen of Paclitaxel and Cyclophosphamide in Mesothelin Positive Multiple Solid Tumors

This Phase I clinical trial, sponsored by the Chinese PLA General Hospital, investigates the safety and feasibility of CRISPR-Cas9 mediated PD-1 gene knockout in CAR-T cells targeting mesothelin-positive solid tumors, particularly pancreatic cancer, cholangiocarcinoma, and ovarian cancer. The market for CAR-T therapies is rapidly expanding, particularly in oncology, with increasing interest in personalized and genetically modified cell therapies. The trial's focus on mesothelin, a promising target in solid tumors, positions it competitively within the CAR-T landscape. However, the trial's current status is 'recruiting,' and further data on safety and efficacy will be critical for attracting potential partnerships or investments. The success of this trial could lead to significant advancements in treatment options for patients with limited responses to existing therapies, thereby enhancing the commercial viability of the asset.

Single-arm, Open-label, Dose-escalating Phase I Clinical Study of PA3-17 Injection in Children and Adolescents With Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma

PersonGen BioTherapeutics is advancing PA3-17 injection, a CAR-T therapy targeting CD7, into a Phase I clinical trial for pediatric and adolescent patients with relapsed/refractory T-ALL/T-LBL. The market for pediatric oncology therapies is expanding, driven by increasing incidences of hematological malignancies and a growing emphasis on targeted therapies. The competitive landscape includes established CAR-T therapies, such as Kymriah and Yescarta, which target different antigens. Successful outcomes in this trial could position PersonGen favorably in the CAR-T market, particularly in the underserved pediatric segment, enhancing its portfolio and potential for partnerships or acquisitions. Diligence should focus on regulatory pathways, safety profiles, and the ability to demonstrate superior efficacy compared to existing therapies.

Matched by modality_normalized: cell therapy

Efficacy and Safety of Tocilizumab in the Treatment of Patients With Respiratory Distress Syndrome and Cytokine Release Syndrome Secondary to COVID-19: a Proof of Concept Study

The clinical trial investigates the efficacy and safety of tocilizumab, an IL-6 receptor antagonist, in patients with COVID-19-related respiratory distress syndrome and cytokine release syndrome (CRS). Given the high mortality rates associated with severe COVID-19 cases, particularly in ICU settings, there is a significant unmet medical need for effective treatments. If successful, this trial could position tocilizumab as a key therapeutic option in the management of severe COVID-19, potentially leading to increased market share in the immunomodulatory space. The competitive landscape includes other IL-6 inhibitors and emerging therapies targeting COVID-19, necessitating thorough diligence on market access and reimbursement strategies.

Matched by modality_normalized: cell therapy

A Phase # Study Evaluating Safety and Efficacy of C-CAR088 Treatment in Subjects With Relapsed or Refractory Multiple Myeloma

C-CAR088 is an investigational CAR T-cell therapy targeting BCMA, specifically designed for patients with relapsed or refractory multiple myeloma. The market for multiple myeloma therapies is expanding, with increasing demand for innovative treatments due to the limitations of existing therapies. The competitive landscape includes established CAR T therapies like Bristol-Myers Squibb's Abecma and GSK's Blenrep. Successful outcomes in this trial could position C-CAR088 favorably within this growing market, potentially leading to significant commercial opportunities. However, the asset's success will depend on demonstrating a favorable safety and efficacy profile compared to existing therapies, as well as navigating regulatory pathways in China and potentially other markets.

Matched by modality_normalized: cell therapy

A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001 + STK-009) in Subjects With Relapsed or Refractory CD19+ Hematologic Malignancies

Synthekine's SYNCAR-001 + STK-009 is positioned in the competitive landscape of CAR T-cell therapies targeting CD19+ hematologic malignancies, specifically Chronic Lymphocytic Lymphoma (CLL) and Non-Hodgkin's Lymphoma (NHL). The combination therapy aims to enhance efficacy and safety profiles compared to existing CD19-targeted therapies. The market for CAR T therapies is rapidly expanding, with significant demand for innovative treatments in relapsed or refractory cases. The trial's focus on safety and tolerability will be critical for future regulatory approvals and market entry. Given the estimated completion date in 2041, Synthekine may face competitive pressures from other emerging therapies and established players in the CAR T space, necessitating robust clinical data to support differentiation.

Matched by modality_normalized: cell therapy

A Phase III Randomized, Controlled Study of Equecabtagene Autoleucel Injection in Subjects With Lenalidomide-Refractory R/R Multiple Myeloma

Equecabtagene Autoleucel Injection (Eque-cel) is being evaluated in a Phase III trial for lenalidomide-refractory relapsed/refractory multiple myeloma (RRMM). The market for multiple myeloma therapies is significant, with increasing demand for innovative treatments due to the limitations of current therapies. Eque-cel, as a CAR-T therapy targeting BCMA, positions itself in a competitive landscape alongside established therapies such as daratumumab and pomalidomide. The success of this trial could enhance Nanjing IASO Biotechnology Co., Ltd.'s market presence and potentially lead to partnerships or acquisitions, given the growing interest in CAR-T therapies. Diligence should focus on the trial's recruitment progress, safety profile, and competitive responses from other companies developing BCMA-targeted therapies.

Matched by modality_normalized: cell therapy

PA3-17 Injection for the Treatment of Subjects With Relapsed/Refractory T-Lymphoblastic Leukemia/Lymphoma: A Single-Arm, Open-Label Phase II Clinical Trial

PersonGen BioTherapeutics is advancing PA3-17, a CAR-T cell therapy targeting CD7, for the treatment of relapsed/refractory T-lymphoblastic leukemia/lymphoma (T-ALL/LBL). The market for CAR-T therapies is rapidly expanding, particularly in hematological malignancies, with significant unmet needs in relapsed/refractory cases. The competitive landscape includes established players like Novartis and Gilead, but PA3-17's unique targeting of CD7 may provide a differentiated therapeutic option. Successful outcomes in this trial could position PersonGen favorably for partnerships or acquisitions, enhancing its market presence in the CAR-T space.

Matched by modality_normalized: cell therapy

CLS-015-TAMSC-LBCL-PR An Exploratory, Investigator Initiated Study to Assess the Safety of Combination of CLS-015 (DFF) With Anti-CD-19 CAR-T Cells in Patients With Stable/ Progressive Large B Cell Lymphoma at Lymphodepletion.

CLS-015 (DFF) is positioned to enhance the efficacy of anti-CD19 CAR-T therapies in patients with large B-cell lymphoma, particularly those with stable or progressive disease during lymphodepletion. The study addresses a significant unmet medical need, as current CAR-T therapies have limited effectiveness in this patient population, with high rates of disease progression. If successful, CLS-015 could capture a niche market within the CAR-T therapy landscape, potentially leading to partnerships with CAR-T developers or positioning as a complementary therapy. The competitive landscape includes existing CAR-T therapies and emerging agents targeting similar patient populations, necessitating a robust clinical profile to differentiate CLS-015. Diligence should focus on the safety profile and the ability to demonstrate improved clinical outcomes over existing therapies.

A Phase 1/2, Open-Label, Multicenter, Non-Randomized, Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) In Subjects With Previously Treated Advanced HER2-Positive Solid Tumors

Bellicum Pharmaceuticals is advancing BPX-603, a HER2-targeted dual-switch CAR-T cell therapy, aimed at treating advanced HER2-positive solid tumors. The market for HER2-targeted therapies is significant, particularly in breast and gastric cancers, where existing therapies may have limited efficacy in heavily pre-treated populations. The suspension of the trial due to dose-limiting toxicity in a related study raises concerns regarding safety and may impact investor confidence and future funding. However, if successful, BPX-603 could provide a novel treatment option in a competitive landscape dominated by established therapies such as trastuzumab and newer agents. The potential for a differentiated safety profile through the dual-switch mechanism may enhance its market positioning.

Matched by modality_normalized: cell therapy

Phase I Clinical Study of Chimeric Antigen Receptor T Cells (C-13-60) in the Treatment of Carcinoembryonic Antigen (CEA) Positive Advanced Malignant Solid Tumors

Chongqing Precision Biotech Co., Ltd is advancing its C-13-60 CAR-T cell therapy targeting CEA-positive advanced malignant solid tumors through a Phase I clinical trial. The trial aims to establish safety, tolerability, and pharmacokinetics while preliminarily assessing efficacy. The targeted patient population includes those with advanced colorectal, esophageal, gastric, pancreatic, non-small cell lung, breast, and cholangiocarcinoma who have exhausted standard treatment options. The success of this trial could position C-13-60 as a novel therapeutic option in a competitive landscape dominated by existing CAR-T therapies and immune checkpoint inhibitors. Given the high unmet need in these indications, particularly in late-stage cancers, there is significant market potential if the therapy demonstrates favorable outcomes. The trial's recruitment status is currently active, with an estimated completion date in 2027, indicating a long-term investment horizon for stakeholders.

CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies

PersonGen BioTherapeutics is advancing a CAR-T cell therapy targeting CD19/CD20 for patients with advanced hematological malignancies. The market for CAR-T therapies is rapidly expanding, particularly in the treatment of B-cell malignancies such as non-Hodgkin lymphoma and acute lymphoblastic leukemia. Given the high unmet need in this patient population, successful outcomes could position PersonGen favorably against established players like Novartis and Gilead. The trial's focus on patients with limited treatment options enhances its potential market appeal. However, the competitive landscape is intense, necessitating robust efficacy and safety data to ensure differentiation.

Matched by modality_normalized: cell therapy

Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer

The clinical study of PSMA-targeted CAR-T cells is positioned in a competitive landscape focused on advanced therapies for castration-resistant prostate cancer (CRPC). Given the high unmet medical need in this patient population, successful outcomes could lead to significant market opportunities, particularly as current treatment options are limited and often ineffective. The trial is sponsored by The Affiliated Hospital of Xuzhou Medical University, indicating potential for collaboration with academic institutions and access to innovative research capabilities. The study's focus on safety and efficacy will be critical for attracting interest from larger biopharma companies for potential partnerships or acquisitions. The trial's recruitment status is active, which is favorable for timely data generation and market entry.

Matched by modality_normalized: cell therapy

A Single Dose-escalation Study to Evaluate the Safety and Efficacy of Allogeneic CAR-T Targeting CD19 Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B Cell Acute Lymphoblastic Leukemia

ThisCART19, an allogeneic CAR-T therapy targeting CD19, is being developed by Fundamenta Therapeutics for the treatment of refractory or relapsed B-cell acute lymphoblastic leukemia (r/r B-ALL). The market for CAR-T therapies is expanding, particularly in hematological malignancies, with increasing demand for innovative treatments due to the high unmet need in this patient population. The competitive landscape includes established players like Novartis and Gilead, which may pose challenges in terms of market entry and pricing strategies. Diligence should focus on the safety and efficacy data emerging from this trial, as well as potential partnerships or collaborations that could enhance market access and distribution.

Matched by modality_normalized: cell therapy

Multi-omic Characterization of Pediatric and Adult Patients Undergoing Hematopoietic Stem Cell Transplantation and Advanced Cell Therapies

The study, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna, aims to elucidate the role of gut microbiota in influencing clinical outcomes in both pediatric and adult patients undergoing HCT and CAR-T therapy. Given the increasing recognition of microbiota's impact on treatment efficacy and safety, the findings could lead to the development of microbiota-informed risk stratification tools and personalized therapeutic strategies. This research may enhance patient outcomes and reduce healthcare costs associated with complications from these therapies. The market for microbiome-related interventions is expanding, with potential applications in antibiotic stewardship and microbiota-modulating therapies. Companies focusing on microbiome research and therapies may find strategic partnerships or investment opportunities arising from this study's outcomes.

Study of Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor T Cell(C-CAR011) Treatment in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

C-CAR011, developed by Shanghai AbelZeta Ltd., targets CD19 for the treatment of relapsed or refractory B cell Non-Hodgkin Lymphoma (NHL). The asset is positioned in a competitive landscape dominated by established CAR-T therapies such as Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel). Given the increasing prevalence of NHL and the unmet need for effective therapies in relapsed cases, C-CAR011 could capture market share if it demonstrates superior efficacy or safety profiles. The trial's single-arm design and focus on a specific patient population may streamline regulatory pathways, but the commercial viability will depend on the robustness of clinical outcomes and pricing strategies in comparison to existing therapies.

Matched by modality_normalized: cell therapy

A Phase 1 Trial to Evaluate the Safety of IL13Rα2-Targeting Chimeric Antigen Receptor (CAR) T Cells With CRISPR Knockout of TGFβR2 in Patients With Recurrent or Progressive High-Grade Glioma (HGG)

The ongoing Phase 1 trial at City of Hope Medical Center aims to evaluate the safety and tolerability of TGFβR2KO/IL13Rα2 CAR T-cell therapy in patients with recurrent or progressive high-grade glioma, specifically glioblastoma and IDH-mutant astrocytoma. The trial's focus on a genetically modified autologous CAR T-cell approach positions it within the rapidly evolving CAR T-cell therapy market, which has seen significant investment and interest due to its potential to address unmet medical needs in oncology. Given the high incidence of glioblastoma and the limited treatment options available, successful outcomes could lead to substantial market opportunities. The collaboration with the National Cancer Institute (NCI) enhances credibility and may facilitate regulatory pathways. However, the competitive landscape includes established CAR T therapies and emerging candidates targeting similar pathways, necessitating a robust differentiation strategy.

Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma

The CNCT19 CAR-T cell therapy is positioned to address a significant unmet need in the treatment of advanced hepatocellular carcinoma (HCC), particularly in patients who are not candidates for surgical intervention or have progressed after standard therapies. The market for HCC therapies is growing, driven by increasing incidence rates and the need for innovative treatments. Competitive landscape includes established CAR-T therapies and emerging candidates targeting HCC. Diligence should focus on the safety profile and efficacy outcomes of CNCT19, as well as potential partnerships or licensing opportunities with industry collaborators like Juventas Cell Therapy Ltd.

Matched by modality_normalized: cell therapy

Exploratory Clinical Study on the Safety and Efficacy of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Myeloid Malignancies

The exploratory clinical trial sponsored by Tongji Hospital aims to evaluate the safety and efficacy of a novel CAR-T cell therapy targeting CD33, CD123, and CLL-1 in patients with relapsed/refractory myeloid malignancies. Given the high unmet medical need in this patient population, particularly in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), successful outcomes could position this therapy favorably in a competitive landscape dominated by existing treatments such as chemotherapy and other immunotherapies. The trial's design includes a dose escalation followed by a dose expansion phase, which may provide critical insights into the therapy's therapeutic window and potential market entry strategy. The anticipated enrollment of 45 subjects suggests a robust dataset for initial efficacy and safety assessments, which could attract interest from potential partners or investors in the biopharmaceutical sector.

Matched by modality_normalized: cell therapy

A Phase 1A/1B Multicenter Study Evaluating the Safety and Efficacy of ALLO-316 With Cyclophosphamide/Fludarabine Lymphodepletion Alone or Including ALLO-647 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)

ALLO-316, an allogeneic CAR T cell therapy targeting CD70, is being evaluated in a Phase 1A/1B study for advanced or metastatic clear cell renal cell carcinoma (ccRCC). The study's design includes a lymphodepletion regimen with cyclophosphamide and fludarabine, with the potential addition of ALLO-647. The ccRCC market is competitive, with established therapies including checkpoint inhibitors and VEGF inhibitors. The successful outcome of this trial could position Allogene Therapeutics favorably against existing treatments, particularly if ALLO-316 demonstrates superior efficacy or safety profiles. Given the unmet need in advanced ccRCC, positive results could lead to significant market opportunities and partnerships.

Matched by modality_normalized: cell therapy

A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) is a PHASE1 clinical asset sponsored by Caribou Biosciences, Inc. in Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma. SEO and diligence focus: CB-010, Cyclophosphamide, Fludarabine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Matched by modality_normalized: cell therapy

An Exploratory Clinical Study to Evaluate the Safety and Efficacy of BZE2204 CD19/CD22/BCMA CAR-T Cells in Subjects With Relapsed or Refractory Active Autoimmune Diseases

BZE2204 represents a novel CAR-T cell therapy targeting multiple antigens (CD19, CD22, and BCMA) for the treatment of relapsed or refractory autoimmune diseases, specifically idiopathic inflammatory myopathies (IIM), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). The market for autoimmune therapies is significant, with increasing demand for innovative treatments due to the limitations of current therapies. The competitive landscape includes other CAR-T therapies and biologics targeting similar conditions, but BZE2204's tri-target approach may provide a unique selling proposition. The trial is currently recruiting, with anticipated completion in late 2027, suggesting a potential market entry around 2028, contingent on successful outcomes. Diligence should focus on safety and efficacy data, as well as regulatory pathways in China and potentially other markets.

Matched by modality_normalized: cell therapy

A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)

Caribou Biosciences, Inc. is advancing CB-010, a CRISPR-edited allogeneic CAR-T cell therapy targeting CD19, for the treatment of refractory Systemic Lupus Erythematosus (SLE). The market for SLE therapies is growing, driven by the increasing prevalence of autoimmune diseases and the need for effective treatments for refractory cases. However, the competitive landscape includes established therapies and emerging biologics, necessitating a robust differentiation strategy. The withdrawal of the trial due to strategic pipeline prioritization indicates a potential shift in focus towards oncology programs, which may impact investor confidence and future funding for autoimmune indications.

Matched by modality_normalized: cell therapy

A Study on the Safety, Preliminary Efficacy, and Cellular Kinetics of Allogeneic CD7-Targeted CAR-T Cell Injection for the Treatment of Type 1 Diabetes Mellitus

The study, sponsored by Shanghai Zhongshan Hospital, aims to evaluate the safety and preliminary efficacy of allogeneic CD7-targeted CAR-T cell therapy for Type 1 Diabetes Mellitus (T1DM). Given the increasing prevalence of T1DM and the limitations of current insulin therapies, this innovative approach could position the sponsor favorably in the emerging immunotherapy market for autoimmune diseases. The potential to modify the underlying autoimmune process may attract interest from investors and partners, particularly if preliminary results demonstrate significant efficacy and safety. The competitive landscape includes other immunomodulatory therapies, but the unique mechanism of action targeting CD7 may provide a distinct advantage. Diligence should focus on regulatory pathways, potential market access challenges, and the need for robust clinical data to support commercialization.

Matched by modality_normalized: cell therapy

A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer

The CAR T-cell therapy targeting EpCAM is positioned to address a significant unmet need in the treatment of relapsed or refractory EpCAM positive cancers, including colon, esophageal, pancreatic, prostate, gastric, and hepatic cancers. The market for CAR T-cell therapies is rapidly expanding, with increasing interest from both pharmaceutical companies and investors. Given the specificity of the therapy, it may offer a competitive edge over broader immunotherapies. The trial's focus on safety and efficacy will be critical for gaining regulatory approval and establishing market presence. The estimated enrollment of 60 patients suggests a targeted approach that may facilitate quicker data collection and analysis, enhancing the asset's attractiveness for potential partnerships or acquisitions.

Matched by modality_normalized: cell therapy

PET-enabled Dual-energy CT for Oncological Applications

This pilot study, sponsored by the University of California, Davis, aims to evaluate a novel imaging technique that combines PET and dual-energy CT to enhance the assessment of bone marrow composition in multiple myeloma patients undergoing CAR T-cell therapy. The potential commercial implications are significant, as advancements in imaging technologies can lead to improved diagnostic capabilities and treatment monitoring in oncology. The study's findings may position UC Davis as a leader in innovative imaging methodologies, attracting partnerships with pharmaceutical companies and imaging device manufacturers. Given the increasing prevalence of multiple myeloma and the growing market for CAR T-cell therapies, successful validation of this imaging method could open avenues for further research funding and commercialization opportunities in the oncology imaging sector.

Matched by modality_normalized: cell therapy

Dual-Target Chimeric Antigen Receptor (CAR) T-Cell Therapy Directed Against Mesothelin and Claudin 18.2 in Patients With Advanced or Metastatic Pancreatic Cancer

Essen Biotech's dual-target CAR-T therapy targeting Mesothelin and Claudin 18.2 represents a novel approach in treating advanced pancreatic adenocarcinoma, a malignancy with limited treatment options and poor prognosis. The dual-target strategy may enhance therapeutic efficacy by addressing antigen heterogeneity, potentially positioning Essen Biotech favorably in the competitive landscape of immunotherapies for pancreatic cancer. The market for pancreatic cancer therapies is growing, driven by increasing incidence rates and the need for effective treatments. Successful outcomes from this trial could lead to significant commercial opportunities, including partnerships, licensing agreements, and market exclusivity, contingent upon favorable safety and efficacy profiles.

Matched by modality_normalized: cell therapy